Visconti Roberta, Morra Francesco, Guggino Gianluca, Celetti Angela
Institute for the Experimental Endocrinology and Oncology "G. Salvatore", Italian National Council of Research, via S. Pansini 5, 80131 Napoli, Italy.
Thoracic Surgery Unit, Antonio Cardarelli Hospital, via A. Cardarelli 9, 80131 Napoli, Italy.
Int J Mol Sci. 2017 Jun 27;18(7):1374. doi: 10.3390/ijms18071374.
Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.
肺癌是全球最常见的癌症。令人失望的是,尽管在鼓励筛查或至少密切监测高危个体方面付出了巨大努力,但大多数肺癌在因局部进展或转移而无法手术切除时才被诊断出来。在这些情况下,首选的治疗方法是化疗,单独使用或与放疗联合使用。在这里,我们将简要回顾在鉴定新型肺癌基因损伤以及开发专门针对这些损伤的新药方面最成功和最新的进展。然而,肺癌仍然是癌症相关死亡的主要原因,这也是因为尽管最初反应令人印象深刻,但患者在治疗几个月后往往会对新型靶向治疗产生耐药性。因此,继续寻找新的治疗选择确实至关重要。所以,在此,基于我们最近关于肿瘤抑制因子CCDC6蛋白在肺癌发生中的作用的研究结果,我们还将讨论我们设想的针对肺癌的新型治疗方法。